Equity
€421,110 from €6.1m in 2011
Equity fell by 93% in 14 years.
AMAKEM
Lifetime
16 annual accounts with figures on one time axispeak €621,521 (2016)
-€8,122▼ €298,092
lowest -€6.8m (2012)
-€5,969▼ €296,798
peak €6.1m (2011)
€421,110▼ 1.4%
€0▼ 100%
peak 9.5 FTE (2015)
-not published
Board12 names since 2014
3 directors and 2 others
Owners6 names in the annual accounts
26.75% and 2 others
Documentsfilings and deeds
19-05-202673 days before the deadline
2025micro format
Gross margin from €289,970 to -€8,122Loss of €5,969Debts from €100,000 to €0
Key points
from the 2025 annual accountsResult
-€5,969 -€5,969
From profit to loss in 2025, after a profit of €290,829 in 2024.
Position in the sector
-€5,969
Lower net result than 95% of companies in human health. Sector median €59,563 · 21,317 companies.
Turnover not published (micro format)
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 6,920 companies had the same profile as AMAKEM has now. Each dot stands for 18 companies, two years later.
90.7%
were still trading
8.0%
stopped another way
1.1%
went bankrupt
Another 0.1% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 6,920 companies, not a prediction for AMAKEM. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Board and ownership
Director,
Director,
Director,
- 26.75%equity €521.2m (2025) · 2025 annual accounts of
- 18.86%equity €4.18bn (2025) · 2025 annual accounts of
- 15.24%score equity €1.6m (2025) · 2025 annual accounts of
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0817285772
Capital decrease of €23,342,579.50 to €420,515
Capital from €23,763,094.50 to €420,515 · Reappointments: , and · Permanent representatives: , and · General meeting of 28-12-2023 · Gazette deed
Resignation: (director)
General meeting of 20-05-2022 · Gazette deed
4 directors reappointed
, , and · Permanent representatives: , and · General meeting of 27-05-2021 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| AMAKEM Hasselt | €0.4m | -€8,122 | 100.0% | - |
| CRYOSTORAGE Ghent | €0.4m | -€453 | -30.2% | - |
| DANOS LABORATORY Ixelles | €0.3m | -€27,299 | 38.0% | - |
| ABBIO Watermael-Boitsfort | €0.4m | -€97,079 | -22.6% | - |
| DName-iT Leuven | €0.5m | -€71,430 | 21.5% | - |
| Expert Service & Advice in Healthcare Hoeilaart | €1.1m | -€857 | 98.2% | - |
| LABEUROP Ottignies-Louvain-la-Neuve | €0.6m | €2,107 | 52.1% | - |
These companies have the same main activity as AMAKEM: medical imaging and medical laboratories (NACE 86910). They are comparable in size and age: total assets between €298,000 and €1.1m, founded between 1998 and 2014.
Official details
Source: KBO- Status
- Active since 23-07-2009Normal situation
- Registered office
- 14 active companies are registered at this addressSource: KBO register, as of 14 November 2026.
- Activity
- Medical imaging and medical laboratoriesNACE 86910
- Establishment unit
- 2.180.461.8123500 Hasselt, since 22-07-2009
- Financial year end
- 31 December
- Peppol
- Reachable since 14-08-2025
Annual accounts 2025
- €421,110▼ 20.1%
- Filing
- Filed on 19-05-2026, 73 days before the end of the filing period
Companies linked to AMAKEM
Shareholders
- 12.06%
Insights on AMAKEM
AMAKEM files the micro format. That format states no turnover. The gross margin rose from -€1.1m in 2010 to -€8,122 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about AMAKEM
- What is the company number of AMAKEM?
- The company number of AMAKEM is 0817.285.772. The VAT number is the same number with BE in front: BE 0817.285.772.
- Where is AMAKEM based?
- The registered office is at Kuringersteenweg 172, 3500 Hasselt.Company details
- What does AMAKEM do?
- According to the KBO register, the main activity is medical imaging and medical laboratories (NACE 86910).
- What is the legal form of AMAKEM?
- AMAKEM is a public limited company (NV).
- When was AMAKEM founded?
- AMAKEM was founded on 23-07-2009.
- Is AMAKEM still active?
- Yes, AMAKEM is an active enterprise in the KBO register.
- What is the turnover of AMAKEM?
- The annual accounts for financial year 2025 state no turnover. The micro format does not require it.Financials
- Is AMAKEM profitable?
- In financial year 2025, AMAKEM made a loss of €5,969.
- Where can I find the annual accounts of AMAKEM?
- AMAKEM filed 16 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of AMAKEM due?
- AMAKEM must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.